Category(s):
Life / BIO Sciences
|
Pharmaceuticals
|
Company Overview
Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company's Lead Candidate, QBI-139, is based on the Company's EVadeT Ribonuclease Technology, which consists of a human pancreatic enzyme, Ribonuclease I engineered to kill cancer cells. The EVadeT Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin.
|